Diabetic Retinopathy Market To 2022 – Market Share, Growth, Trends: Grand View Research, Inc.

  • Published on
    17-Jul-2015

  • View
    212

  • Download
    0

Transcript

  • Diabetic Retinopathy Market By Type (Proliferative DR,

    Non-Proliferative DR) By Management (Anti-VEGF

    Therapy, Intraocular Steroid Injection, Laser Surgery,

    Vitrectomy) Is Expected To Reach USD 10.11 Billion By

    2022: Grand View Research, Inc.

    Global Diabetic Retinopathy Market is expected to reach USD 10.11 billion by 2022, according

    to a new study by Grand View Research Inc. Diabetic retinopathy is considered as a serious sight

    threatening complication that results due to long term diabetes. The treatment line selection for

    diabetic retinopathy depends on the severity of the condition and may require intraocular

    injections, anti VEGF drugs, laser surgery or vitrectomy. Increasing incidences of diabetes,

    rising geriatric population base and the growing demand for early detection are some high impact

    rendering drivers of the diabetic retinopathy market. Furthermore, improving healthcare

    infrastructure, rising demand for cost-effective and safe treatment and rising focus of market

    players on emerging nations such as India and China are also anticipated to propel market

    growth. Presence of supportive government initiatives such as the Queen Elizabeth Diamond

    Jubilee Trust, which is taking initiatives for increasing patient awareness levels in order to

    promote regular retinal screening and early laser surgery to prevent permanent visual impairment

    and Ophthalmic Society of South Africa which works towards the improvement of

    reimbursement policies are anticipated to fuel the growth of the diabetic retinopathy market over

    the forecast period.

    View summary of this report @ http://www.grandviewresearch.com/industry-

    analysis/diabetic-retinopathy-market

  • Global diabetic retinopathy market, by type, 2012-2022 (USD Million)

    Table of Content

    Chapter 1 Methodology and Scope

    1.1 Research Methodology

    1.2 Research Scope & Assumptions

    1.3 List of Data Sources

    Chapter 2 Executive Summary

    Chapter 3 Diabetic Retinopathy Industry Outlook

    3.1 Market segmentation

    3.2 Market size and growth prospects

    3.3 Diabetic retinopathy market dynamics

    3.4 Market driver analysis

    3.4.1 Increasing prevalence of diabetes

    3.4.2 Growing global geriatric population base

    3.4.3 Increasing incidences of blindness due to diabetes

    3.5 Market restraint analysis

    3.5.1 Lack of accurate diagnosis

    3.5.2 Extended approval time for drugs

    3.5.3 Lack of trained ophthalmologists

  • 3.6 Diabetic retinopathy: Epidemiology & guidelines

    3.7 Diabetic retinopathy: Pipeline overview

    3.8 Key Opportunities Prioritized

    3.9 Diabetic retinopathy company market share, 2014

    3.10 Industry analysis Porters

    3.11 Diabetic retinopathy PESTEL Analysis

    Chapter 4 Diabetic Retinopathy Type Outlook

    4.1 Diabetic retinopathy revenue share by type, 2014 & 2022

    4.2 Proliferative diabetic retinopathy

    4.2.1 Proliferative diabetic retinopathy market, 2012 2022 (USD Million)

    4.3 Non-proliferative diabetic retinopathy

    4.3.1 Non-proliferative diabetic retinopathy market, 2012 2022 (USD Million)

    Chapter 5 Diabetic Retinopathy Management Outlook

    5.1 Diabetic retinopathy revenue share, by management, 2014 & 2022

    5.2 Anti-VEGF therapy

    5.2.1 Anti-VEGF therapy market, 2012 2022 (USD Million)

    5.3 Intraocular steroid injection

    5.3.1 Intraocular steroid injection market, 2012 2022 (USD Million)

    5.4 Laser surgery

    5.4.1 Laser surgery market, 2012 2022 (USD Million)

    5.5 Vitrectomy

    5.5.1 Vitrectomy market, 2012 2022 (USD Million)

    Chapter 6 Diabetic Retinopathy Regional Outlook

    6.1 Diabetic retinopathy revenue share, by region, 2014 & 2022

    6.2 North America diabetic retinopathy market

    6.2.1 North America diabetic retinopathy market, 2012 2022 (USD Million)

    6.2.2 U.S. diabetic retinopathy market

    6.2.2.1 U.S. diabetic retinopathy market, 2012 2022 (USD Million)

    6.2.3 Canada diabetic retinopathy market

    6.2.3.1 Canada diabetic retinopathy market, 2012 2022 (USD Million)

    6.3 Europe diabetic retinopathy market

    6.3.1 Europe diabetic retinopathy market, 2012 2022 (USD Million)

    6.3.2 Germany diabetic retinopathy market

    6.3.2.1 Germany diabetic retinopathy market, 2012 2022 (USD Million)

    6.3.3 UK diabetics retinopathy

    6.3.3.1 UK diabetic retinopathy market, 2012 2022 (USD Million)

    6.4 Asia Pacific diabetic retinopathy market

    6.4.1 Asia Pacific diabetic retinopathy market, 2012 2022 (USD Million)

  • 6.4.2 China diabetic retinopathy market

    6.4.2.1 China diabetic retinopathy market, 2012 2022 (USD Million)

    6.4.3 Japan diabetic retinopathy market

    6.4.3.1 Japan diabetic retinopathy market, 2012 2022 (USD Million)

    6.5 Latin America diabetic retinopathy market

    6.5.1 Latin America diabetic retinopathy market, 2012 2022 (USD Million)

    6.5.2 Brazil diabetic retinopathy market

    6.5.2.1 Brazil diabetic retinopathy market, 2012 2022 (USD Million)

    6.6 MEA diabetic retinopathy market

    6.6.1.1 MEA diabetic retinopathy market, 2012 2022 (USD Million)

    6.6.2 South Africa diabetic retinopathy market

    6.6.2.1 South Africa diabetic retinopathy market, 2012 2022 (USD Million)

    Chapter 7 Competitive Landscape

    7.1 Bayer Healthcare

    7.1.1 Company Overview

    7.1.2 Financial Performance

    7.1.3 Product Benchmarking

    7.1.4 Strategic Initiatives

    7.2 Novartis AG

    7.2.1 Company Overview

    7.2.2 Financial Performance

    7.2.3 Product Benchmarking

    7.2.4 Strategic Initiatives

    7.3 Regeneron Pharmaceuticals Inc.

    7.3.1 Company Overview

    7.3.2 Financial Performance

    7.3.3 Product Benchmarking

    7.3.4 Strategic Initiatives

    7.4 Actavis PLC

    7.4.1 Company Overview

    7.4.2 Financial Performance

    7.4.3 Product Benchmarking

    7.4.4 Strategic Initiatives

    7.5 ThromboGenics

    7.5.1 Company Overview

    7.5.2 Financial Performance

    7.5.3 Product Benchmarking

    7.5.4 Strategic Initiatives

  • 7.6 Sirnaomics Incorporation

    7.6.1 Company Overview

    7.6.2 Financial Performance

    7.6.3 Product Benchmarking

    7.7 Genentech

    7.7.1 Company Overview

    7.7.2 Financial Performance

    7.7.3 Product Benchmarking

    7.7.4 Strategic Initiatives

    7.8 Glycadia Pharmaceuticals

    7.8.1 Company Overview

    7.8.2 Financial Performance

    7.8.3 Product Benchmarking

    7.9 Alimera Sciences

    7.9.1 Company Overview

    7.9.2 Financial Performance

    7.9.3 Product Benchmarking

    7.9.4 Strategic Initiatives

    7.10 Ampio Pharmaceuticals

    7.10.1 Company Overview

    7.10.2 Financial Performance

    7.10.3 Product Benchmarking

    7.10.4 Strategic Initiatives

    7.11 BCN Peptides

    7.11.1 Company Overview

    7.11.2 Financial Performance

    7.11.3 Product Benchmarking

    7.11.4 Strategic Initiatives

    7.12 Kowa Group

    7.12.1 Company Overview

    7.12.2 Financial Performance

    7.12.3 Product Benchmarking

    7.12.4 Strategic Initiatives

    Browse full report @ http://www.grandviewresearch.com/industry-analysis/diabetic-

    retinopathy-market

  • List of Tables

    TABLE 1 Diabetic Retinopathy - Industry Snapshot & Key Buying Criteria, 2012-2022

    TABLE 2 Global diabetic retinopathy market, by type, 2012 - 2022 (USD Million)

    TABLE 3 Global diabetic retinopathy market, by management, 2012 - 2022 (USD Million)

    TABLE 4 Global diabetic retinopathy market, by region, 2012 - 2022 (USD Million)

    TABLE 5 Diabetic retinopathy - Key market driver analysis

    TABLE 6 North America diabetes prevalence (national prevalence %), 2013 & 2035

    TABLE 7 Europe diabetes prevalence (national prevalence %), 2013 & 2035

    TABLE 8 Latin America diabetes prevalence (national prevalence %), 2013 & 2035

    TABLE 9 MENA and Africa diabetes prevalence (national prevalence %), 2013 & 2035

    TABLE 10 CIS diabetes prevalence (national prevalence %), 2013 & 2035

    TABLE 11 Asia Pacific diabetes prevalence (national prevalence %), 2013 & 2035

    TABLE 12 Diabetic retinopathy - Key market restraint analysis

    TABLE 13 Recent guidelines for diabetic retinopathy

    TABLE 14 Regional specific diabetes and diabetic retinopathy epidemiology

    TABLE 15 Diabetic retinopathy: Pipeline overview

    TABLE 16 North America diabetic retinopathy market, by region, 2012 - 2022 (USD Million)

    TABLE 17 North America diabetic retinopathy market, by type, 2012 - 2022 (USD Million)

    TABLE 18 North America Diabetic Retinopathy market, by management, 2012 - 2022 (USD

    Million)

    TABLE 19 U.S. diabetic retinopathy market, by type, 2012 - 2022 (USD Million)

    TABLE 20 U.S. Diabetic Retinopathy market, by management, 2012 - 2022 (USD Million)

    TABLE 21 Canada diabetic retinopathy market, by type, 2012 - 2022 (USD Million)

    TABLE 22 Canada diabetic retinopathy market, by management, 2012 - 2022 (USD Million)

    TABLE 23 Europe diabetic retinopathy market, by region, 2012 - 2022 (USD Million)

    TABLE 24 Europe diabetic retinopathy market, by type, 2012 - 2022 (USD Million)

    TABLE 25 Europe diabetic retinopathy market, by management, 2012 - 2022 (USD Million)

    TABLE 26 Germany diabetic retinopathy market, by type, 2012 - 2022 (USD Million)

    TABLE 27 Germany diabetic retinopathy market, by management, 2012 - 2022 (USD Million)

    TABLE 28 UK diabetic retinopathy market, by type, 2012 - 2022 (USD Million)

    TABLE 29 UK diabetic retinopathy market, by management, 2012 - 2022 (USD Million)

    TABLE 30 Asia Pacific diabetic retinopathy market, by region, 2012 - 2022 (USD Million)

    TABLE 31 Asia Pacific diabetic retinopathy market, by type, 2012 - 2022 (USD Million)

    TABLE 32 Asia Pacific diabetic retinopathy market, by management, 2012 - 2022 (USD

    Million)

    TABLE 33 China diabetic retinopathy market, by type, 2012 - 2022 (USD Million)

    TABLE 34 China diabetic retinopathy market, by management, 2012 - 2022 (USD Million)

    TABLE 35 Japan diabetic retinopathy market, by type, 2012 - 2022 (USD Million)

    TABLE 36 Japan diabetic retinopathy market, by management, 2012 - 2022 (USD Million)

    TABLE 37 Latin America diabetic retinopathy market, by region, 2012 - 2022 (USD Million)

    TABLE 38 Latin America diabetic retinopathy market, by type, 2012 - 2022 (USD Million)

    TABLE 39 Latin America diabetic retinopathy market, by management, 2012 - 2022 (USD

    Million)

  • TABLE 40 Brazil diabetic retinopathy market, by type, 2012 - 2022 (USD Million)

    TABLE 41 Brazil diabetic retinopathy market, by management, 2012 - 2022 (USD Million)

    TABLE 42 MEA diabetic retinopathy market, by region, 2012 - 2022 (USD Million)

    TABLE 43 MEA diabetic retinopathy market, by type, 2012 - 2022 (USD Million)

    TABLE 44 MEA diabetic retinopathy market, by management, 2012 - 2022 (USD Million)

    TABLE 45 South Africa diabetic retinopathy market, by type, 2012 - 2022 (USD Million)

    TABLE 46 South Africa diabetic retinopathy market, by management, 2012 - 2022 (USD

    Million)

    For More Information visit http://www.grandviewresearch.com/industry-analysis/diabetic-

    retinopathy-market

    List of Figures

    FIG. 1 Diabetic Retinopathy: Market segmentation

    FIG. 2 Global diabetic retinopathy market, 2012 - 2022 (USD Million)

    FIG. 3 Diabetic retinopathy market dynamics

    FIG. 4 Diabetes prevalence of top 10 countries in 2013 in the age group of 20 to 79 years

    (million)

    FIG. 5 Current and projected prevalence of diabetes, by geography, 2013 & 2035 (% increase)

    FIG. 6 Rising geriatric population, by geography, 2013 & 2035 (% increase)

    FIG. 7 Growth in diabetic retinopathy cases according to age and gender (%)

    FIG. 8 Occurrence of blindness in diabetic patients, by age group (2009) (in percentage)

    FIG. 9 Ophthalmologist growth rate v/s population growth rate, 2010

    FIG. 10 Key opportunities prioritized

    FIG. 11 Diabetic retinopathy company market share, 2014

    FIG. 12 Diabetic retinopathy market Porters analysis FIG. 13 Diabetic retinopathy PESTEL analysis

    FIG. 14 Diabetic retinopathy revenue share by type, 2014 & 2022

    FIG. 15 Proliferative diabetic retinopathy market, 2012 - 2022 (USD Million)

    FIG. 16 Non-proliferative diabetic retinopathy market, 2012 - 2022 (USD Million)

    FIG. 17 Diabetic retinopathy revenue share, by management, 2014 & 2022

    FIG. 18 Anti-VEGF therapy market, 2012 - 2022 (USD Million)

    FIG. 19 Intraocular steroid injection market, 2012 - 2022 (USD Million)

    FIG. 20 Laser surgery market, 2012 - 2022 (USD Million)

    FIG. 21 Vitrectomy market, 2012 - 2022 (USD Million)

    FIG. 22 Diabetic retinopathy revenue share, by region, 2014 & 2022

    FIG. 23 North America diabetic retinopathy market, 2012 - 2022 (USD Million)

    FIG. 24 U.S. diabetic retinopathy distribution, by age, 2012

  • FIG. 25 U.S. diabetic retinopathy market, 2012 - 2022 (USD Million)

    FIG. 26 Canada diabetic retinopathy market, 2012 - 2022 (USD Million)

    FIG. 27 Europe diabetic retinopathy market, 2012 - 2022 (USD Million)

    FIG. 28 Germany diabetic retinopathy market, 2012 - 2022 (USD...

Recommended

View more >